Fig. 2From: Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, CanadaOverall survival with 2nd line ipilimumab and historical controls (a) Unadjusted (b) IPTW weightedBack to article page